Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Exemestane
Drug ID BADD_D00861
Description Exemestane is an oral steroidal aromatase inhibitor used in the adjuvant treatment of hormonally-responsive (also called hormone-receptor-positive, estrogen-responsive) breast cancer in postmenopausal women. It irreversibly binds to the active site of the enzyme resulting in permanent inhibition.
Indications and Usage For the treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy.
Marketing Status Prescription
ATC Code L02BG06
DrugBank ID DB00990
KEGG ID D00963
MeSH ID C056516
PubChem ID 60198
TTD Drug ID D0D2VS
NDC Product Code 62157-091; 51991-005; 59057-007; 73377-132; 64918-0621; 50090-5193; 52128-134; 63629-2056; 59057-008; 69097-316; 0009-7663; 62756-981; 68382-383; 64181-0005; 0832-0595; 44278-025; 0378-5001; 65427-030; 71921-190; 46439-8746; 49386-026; 65162-240; 53104-7666; 47781-108; 59762-2858; 0054-0080; 65129-1217; 70771-1374; 64918-0622; 65089-0046
Synonyms exemestane | examestane | 6-methyleneandrosta-1,4-diene-3,17-dione | FCE 24304 | FCE-24304 | Aromasil | Aromasin | Aromasine
Chemical Information
Molecular Formula C20H24O2
CAS Registry Number 107868-30-4
SMILES CC12CCC3C(C1CCC2=O)CC(=C)C4=CC(=O)C=CC34C
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Cardiovascular disorderAdenylate kinase isoenzyme 1P00568Not Available9456245; 10473018; 14623544; 10514021; 10388095; 9556789; 15814851; 14513432; 11850229; 14687601; 15083379
OsteoporosisAdenylate kinase isoenzyme 1P00568Not Available9456245; 10473018; 14623544; 10514021; 10388095; 9556789; 15814851; 14513432; 11850229; 14687601; 15083379
Urogenital disorderAdenylate kinase isoenzyme 1P00568Not Available9456245; 10473018; 14623544; 10514021; 10388095; 9556789; 15814851; 14513432; 11850229; 14687601; 15083379
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Joint stiffness15.01.02.0030.007189%Not Available
Joint swelling15.01.02.0040.009585%Not Available
Laryngitis22.07.03.001; 11.01.13.0010.004793%
Leukopenia01.02.02.0010.011982%Not Available
Liver disorder09.01.08.001--Not Available
Lymphadenopathy01.09.01.0020.004793%Not Available
Lymphoedema24.09.01.001; 01.09.01.0060.009585%
Malaise08.01.01.0030.059908%
Memory impairment19.20.01.003; 17.03.02.0030.011982%
Menopausal symptoms21.02.02.002--Not Available
Metastases to lung16.22.02.002; 22.08.01.0050.001250%Not Available
Metrorrhagia21.01.01.0060.007189%Not Available
Migraine24.03.05.003; 17.14.02.0010.007189%Not Available
Multiple fractures15.08.02.005; 12.04.02.009--Not Available
Muscle spasms15.05.03.004--
Muscular weakness17.05.03.005; 15.05.06.0010.016774%
Musculoskeletal pain15.03.04.0070.009585%
Myalgia15.05.02.0010.035945%
Myocardial infarction24.04.04.009; 02.02.02.007--
Myocardial ischaemia24.04.04.010; 02.02.02.008--Not Available
Nasal congestion22.04.04.0010.004793%
Nasopharyngitis22.07.03.002; 11.01.13.0020.016774%Not Available
Nausea07.01.07.001--
Neoplasm16.16.02.0010.001875%Not Available
Neoplasm malignant16.16.01.0010.008127%Not Available
Nervous system disorder17.02.10.001--Not Available
Nervousness19.06.02.0030.009585%Not Available
Neuropathy peripheral17.09.03.0030.009585%Not Available
Neutropenia01.02.03.004--Not Available
Oedema14.05.06.010; 08.01.07.0060.007189%Not Available
The 5th Page    First    Pre   5 6 7 8 9    Next   Last    Total 10 Pages